| Not Yet Recruiting | Clinical Study of Recombinant Anti-CD19m-CD3 Antibody Injection (A-319) NCT07371533 | Shanxi Bethune Hospital | N/A |
| Recruiting | Co-Transplant of an Unmodified Haplo-Identical Graft With Cord Blood NCT06904482 | Case Comprehensive Cancer Center | Phase 2 |
| Recruiting | BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B-ALL NCT07008885 | Chinese PLA General Hospital | Phase 1 / Phase 2 |
| Recruiting | TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-ALL NCT06481735 | Chinese PLA General Hospital | Phase 1 / Phase 2 |
| Active Not Recruiting | A Study to Learn About the Safety of BESPONSA Injection in Pediatric Patients With Acute Lymphocytic Leukemia. NCT06476665 | Pfizer | — |
| Recruiting | A Novel CAR-T Combined Expression of IL-15 in the Treatment of Malignant Hematological Tumors NCT06783816 | Shanxi Bethune Hospital | N/A |
| Recruiting | Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution NCT06131801 | Children's Hospital Medical Center, Cincinnati | — |
| Withdrawn | A Dose Escalation Study of Intensity Modulated Total Marrow Irradiation (IMRT-TMI) Followed by Fludarabine as NCT05201183 | Naoyuki G. Saito, M.D., Ph.D. | Phase 1 / Phase 2 |
| Completed | Safety and Clinical Activity of KT-253 in Adult Patients with High Grade Myeloid Malignancies, Acute Lymphocyt NCT05775406 | Kymera Therapeutics, Inc. | Phase 1 |
| Recruiting | Allo HSCT Using RIC and PTCy for Hematological Diseases NCT05805605 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Recruiting | Pilot Imaging Study of Leukemia NCT03633955 | University of Oklahoma | Phase 1 |
| Recruiting | CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or R NCT05442515 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Active Not Recruiting | Efficacy and Safety of Inotuzumab Ozogamicin in Treating Adult Patients With Ph Negative ALL With Minimal Resi NCT05456698 | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 |
| Withdrawn | Cryopreserved MMUD BM With PTCy for Hematologic Malignancies NCT05170828 | Ossium Health, Inc. | Phase 1 |
| Unknown | Anti-CD19 CAR-Engineered NK Cells in the Treatment of Relapsed/Refractory B-cell Malignancies NCT05410041 | Beijing Boren Hospital | Phase 1 |
| Unknown | CD19-targeted CAR T Cells for Patients With Relapsed or Refractory in B-cell Acute Lymphoblastic Leukemia NCT05727683 | Shanghai Ming Ju Biotechnology Co., Ltd. | Phase 1 |
| Terminated | A Triple-targeted Cell Preparation Targeting CD19/CD20/CD22 in Patients With Relapsed/Refractory B-cell Acute NCT05292898 | Institute of Hematology & Blood Diseases Hospital, China | Phase 1 |
| Completed | A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia NCT05326516 | Syndax Pharmaceuticals | Phase 1 |
| Active Not Recruiting | Duvelisib Following Chimeric Antigen Receptor T-Cell Therapy NCT05044039 | Washington University School of Medicine | Phase 1 |
| Recruiting | Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CM NCT04771572 | Newave Pharmaceutical Inc | Phase 1 |
| Unknown | Cord Blood Derived Anti-CD19 CAR-Engineered NK Cells for B Lymphoid Malignancies NCT04796675 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 1 |
| Unknown | Genetic Polymorphisms in Drug Induced Neuropathy in Children With ALL NCT05811910 | IRCCS Burlo Garofolo | — |
| Completed | Effects of Prebiotics on Gut Microbiome in Patients Undergoing HSCT NCT04629430 | University of Virginia | N/A |
| Completed | Assessing the Ontogeny of P-glycoprotein Expression in Blood of Pediatric Leukemic Patients NCT05021159 | Tanta University | — |
| Recruiting | Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or So NCT03934372 | Incyte Biosciences International Sàrl | Phase 1 / Phase 2 |
| Withdrawn | Randomized Study: Standard of Care With or Without Atorvastatin for Prevention of GVHD for Matched Unrelated D NCT03066466 | Loyola University | Phase 3 |
| Completed | Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cel NCT03755414 | Washington University School of Medicine | Phase 1 |
| Unknown | CD7 CAR-T Cells for Patients With R/R CD7+ NK/T Cell Lymphoma,T-lymphoblastic Lymphoma and Acute Lymphocytic L NCT04004637 | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Phase 1 |
| Unknown | Senl_1904A and Senl_1904B Chimeric Antigen Receptor （CAR） T-Cell in the Treatment of r/ r Acute B Lymphocytic NCT03840317 | Hebei Senlang Biotechnology Inc., Ltd. | Phase 1 |
| Active Not Recruiting | Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy NCT03674411 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Completed | A Trial to Evaluate the Potential Impact of Renal Impairment on the Pharmacokinetics and Safety of CPX-351 NCT03555955 | Jazz Pharmaceuticals | Phase 1 |
| Terminated | IMRT-TMI With Fludarabine as Myeloablative Conditioning for Allogeneic HSCT NCT03696537 | Naoyuki G. Saito, M.D., Ph.D. | Phase 1 |
| Completed | BESPONSA Injection 1 mg Special Investigation NCT05923112 | Pfizer | — |
| Completed | CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD NCT03448393 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractor NCT03263637 | AstraZeneca | Phase 1 |
| Recruiting | Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia NCT03104491 | Leland Metheny | Phase 1 / Phase 2 |
| Unknown | A Study of Anti-CD19 CAR-T Cell Immunotherapy for Refractory /Relapsed B Cell Malignancies NCT03191773 | Second Affiliated Hospital of Guangzhou Medical University | Phase 1 / Phase 2 |
| Completed | Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies NCT03056339 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Withdrawn | StemRegenin-1 Expanded vs Unexpanded UCB for High Risk Heme Malignancies NCT02765997 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Completed | Allo HSCT Using RIC for Hematological Diseases NCT02661035 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Terminated | Haploidentical Stem Cell Transplantation Using Post-Transplant Cyclophosphamide NCT03088709 | Loyola University | Phase 2 |
| Completed | Low-Dose Daunorubicin in Relapsed/Refractory Acute Leukemia NCT02914977 | Tara Lin | Phase 1 |
| Unknown | CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma NCT02819583 | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Phase 1 / Phase 2 |
| Unknown | PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia a NCT02892695 | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Phase 1 / Phase 2 |
| Unknown | Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymp NCT02851589 | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Phase 1 / Phase 2 |
| Terminated | Azacitidine in Haploidentical Donor Hematopoietic Cell Transplantation NCT02750254 | Washington University School of Medicine | Phase 1 |
| Completed | Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies NCT03076437 | Shenzhen Institute for Innovation and Translational Medicine | Phase 1 / Phase 2 |
| Completed | BuCY vs TBICY Conditioning Regimen for Standard-risk ALL Undergoing Allo-HSCT NCT02670252 | Nanfang Hospital, Southern Medical University | Phase 3 |
| Completed | Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis NCT02593123 | Virginia Commonwealth University | Phase 2 |
| Completed | Reduced Intensity Conditioning Transplant Using Haploidentical Donors NCT02581007 | Northside Hospital, Inc. | Phase 2 |
| Completed | Use Feasibility of the iThermonitor in Pediatrics Patients on Myelosuppresive Therapies NCT02410252 | Massachusetts General Hospital | N/A |
| Unknown | Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies NCT02456350 | Shenzhen Second People's Hospital | Phase 1 |
| Completed | Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing NCT02315612 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Tr NCT02129582 | Case Comprehensive Cancer Center | Phase 1 |
| Completed | Safety and Tolerability of HSC835 in Patients With Hematological Malignancies Undergoing Single Umbilical Cord NCT01930162 | Novartis Pharmaceuticals | Phase 2 |
| Completed | A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Re NCT02141828 | Epizyme, Inc. | Phase 1 |
| Completed | Pilot Study of Redirected Autologous T Cells Engineered to Contain Humanized Anti-CD19 in Patients With Relaps NCT02374333 | University of Pennsylvania | Phase 1 |
| Recruiting | Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN NCT01853631 | Baylor College of Medicine | Phase 1 |
| Withdrawn | T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies NCT01163201 | Masonic Cancer Center, University of Minnesota | Phase 1 / Phase 2 |
| Terminated | Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic NCT02043587 | University of California, San Diego | Phase 2 |
| Completed | Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell Transplant NCT01634217 | Masonic Cancer Center, University of Minnesota | Phase 1 |
| Completed | Transfusional Iron Overload Among Leukemia Survivors NCT01965171 | St. Jude Children's Research Hospital | — |
| Completed | Human Placental-Derived Stem Cell Transplantation NCT01586455 | New York Medical College | Phase 1 |
| Terminated | Randomized HaploCord Blood Transplantation vs. Double Umbilical Cord Blood Transplantation for Hematologic Mal NCT01745913 | Weill Medical College of Cornell University | Phase 2 |
| Completed | Phase I/II Study of DFP-10917 in Patients With Acute Leukemia NCT01702155 | Delta-Fly Pharma, Inc. | Phase 1 / Phase 2 |
| Completed | Double Cord Versus Haploidentical (BMT CTN 1101) NCT01597778 | Medical College of Wisconsin | Phase 3 |
| Completed | Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning NCT01572662 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Safety and Tolerability of HSC835 in Patients With Hematological Malignancies NCT01474681 | Novartis Pharmaceuticals | Phase 1 / Phase 2 |
| Completed | Safety & Efficacy of Atorvastatin for Prophylaxis of Acute Graft Versus Host Disease in Patients With Hematolo NCT01491958 | Ohio State University Comprehensive Cancer Center | Phase 2 |
| Completed | Effect of Oral Supplementation With a Fibre Enriched Paediatric Sip Feed For Children With Acute Lymphocytic L NCT01600781 | Children's Cancer Hospital Egypt 57357 | N/A |
| Terminated | Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell NCT01500161 | Texas Oncology Cancer Center | Phase 2 |
| Active Not Recruiting | In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Target NCT01430390 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Completed | Study Evaluating Inotuzumab Ozogamicin In Acute Lymphocytic Leukemia NCT01363297 | Pfizer | Phase 2 |
| Completed | Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow Transplantation NCT01338987 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Allo CART-19 Protocol NCT01551043 | University of Pennsylvania | Phase 1 |
| Completed | Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor NCT01350245 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 2 |
| Completed | Safety and Efficacy of 72-hour and 120-hour Infusion of Rigosertib in Acute Myeloid Leukemia (AML) and Acute L NCT01167166 | Traws Pharma, Inc. | Phase 1 / Phase 2 |
| Withdrawn | Phase II Study of VELCADE for Relapsed or Refractory T-cell Prolymphocytic Leukemia NCT01162031 | Stanford University | Phase 2 |
| Completed | Belinostat and Bortezomib in Treating Patients With Relapsed or Refractory Acute Leukemia or Myelodysplastic S NCT01075425 | Virginia Commonwealth University | Phase 1 |
| Unknown | PR104 in Treating Patients With Refractory/Relapsed Acute Leukemia NCT01037556 | Proacta, Incorporated | Phase 1 / Phase 2 |
| Terminated | Safety Study of ON 013105 in Lymphoma and Acute Lymphoid Leukemia NCT01049113 | Traws Pharma, Inc. | Phase 1 |
| Completed | RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia NCT00968253 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Completed | Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or R NCT00990587 | University Health Network, Toronto | Phase 1 |
| Completed | Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloa NCT00975975 | Indiana University School of Medicine | Phase 2 |
| Terminated | Study Evaluating the Tolerance and Biological Activity of Oral Clioquinol in Patients With Relapsed or Refract NCT00963495 | University Health Network, Toronto | Phase 1 |
| Active Not Recruiting | CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL & CLL NCT00586391 | Baylor College of Medicine | Phase 1 |
| Completed | Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS) NCT00854646 | Traws Pharma, Inc. | Phase 1 |
| Completed | Umbilical Cord Blood (UCB) Transplantation in Pediatric Patients With High Risk Leukemia and Myelodysplasia NCT02007863 | University of Miami | N/A |
| Completed | Reduced Intensity Conditioning With Clofarabine, Antithymocyte Globulin (ATG), Total Lymphoid Irradiation (TLI NCT00697684 | Beth Israel Deaconess Medical Center | Phase 1 |
| Completed | INCB018424 in Patients With Advanced Hematologic Malignancies NCT00674479 | M.D. Anderson Cancer Center | Phase 2 |
| Terminated | In-Vivo Activated T-Cell Depletion to Prevent GVHD NCT00594308 | Indiana University | N/A |
| Terminated | Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in NCT00852709 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 1 |
| Completed | Sharing Our Strength: A Research Study for Bone Marrow/Stem Cell Transplant Survivors NCT00701844 | University of North Carolina, Chapel Hill | N/A |
| Completed | Stem Cell Transplantation for Patients With Cancers of the Blood NCT00467961 | National Heart, Lung, and Blood Institute (NHLBI) | Phase 2 |
| Terminated | Liposomal Annamycin in Children and Young Adults With Refractory or Relapsed ALL or AML NCT00430443 | Callisto Pharmaceuticals | Phase 1 |
| Completed | Single vs Double Umbilical Cord Blood Transplants in Children With High Risk Leukemia and Myelodysplasia (BMT NCT00412360 | Medical College of Wisconsin | Phase 3 |
| Completed | Alemtuzumab (CAMPATH 1H) Associated to G-CSF in Adult Patients With Refractory Acute Lymphocytic Leukemia NCT00773149 | Assistance Publique - Hôpitaux de Paris | Phase 1 / Phase 2 |
| Completed | A Study of Low-Dose Decitabine in Relapsed or Refractory Acute Lymphocytic Leukemia (ALL) NCT00349596 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Safety and Tolerability Study of INNO-406 to Treat Chronic Myeloid Leukemia or Acute Lymphocytic Leukemia NCT00352677 | CytRx | Phase 1 |
| Completed | Monoclonal Antibody (mAb) 216 With Chemotherapy in Adult Relapsed or Refractory B-Lineage Acute Lymphoblastic NCT00313079 | Steven E. Coutre | Phase 1 |
| Unknown | Study of Liposomal Annamycin in Patients With Refractory or Relapsed Acute Lymphocytic Leukemia NCT00271063 | Callisto Pharmaceuticals | Phase 1 / Phase 2 |
| Completed | Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases NCT00309842 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Completed | HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With NCT00145626 | St. Jude Children's Research Hospital | Phase 2 |
| Unknown | Tacrolimus and MMF as Post Grafting Immunosuppression After Conditioning With Flu TBI for HLA Matched Family D NCT00304720 | Colorado Blood Cancer Institute | Phase 2 |
| Completed | Infusion of Specially Treated Umbilical Cord Stem Cells After Chemoradiation Treatment for Blood Cancers NCT00089596 | ViaCell | Phase 1 / Phase 2 |
| Unknown | Establishment of Acute Lymphocytic Leukemia Data Base in the Department of Oncology NCT01310946 | King Faisal Specialist Hospital & Research Center | — |
| Completed | Experimental Bone Marrow Transplant Protocol NCT00061581 | National Heart, Lung, and Blood Institute (NHLBI) | Phase 2 |
| Unknown | Studies on the Significance of CXCR4-CXCL12 on Leukemic Cells Passing Through"Marrow-Blood Barrier" NCT00155844 | National Taiwan University Hospital | — |
| Completed | Phase II Study Evaluating Busulfan and Fludarabine as Preparative Therapy in Adults With Hematopoietic Disorde NCT00516152 | University of California, San Francisco | Phase 2 |
| Completed | Investigation of Clofarabine in Acute Leukemias NCT00098033 | University of Texas | Phase 2 |
| Unknown | Treatment of Philadelphia-Positive Acute Lymphocytic Leukemia (Ph+ ALL) in the Elderly With Imatinib Mesylate NCT00149136 | Hospices Civils de Lyon | Phase 2 |
| Completed | Nonmyeloablative Allogeneic Transplant NCT01272817 | Scripps Health | N/A |
| Recruiting | The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Trans NCT01890486 | Wake Forest University Health Sciences | — |
| Completed | CINJALL: Treatment for Children With Acute Lymphocytic Leukemia NCT00176462 | Rutgers, The State University of New Jersey | Phase 2 |
| Completed | Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant NCT00571662 | University of Nebraska | Phase 2 |
| Completed | A Pharmacokinetic and Pharmacodynamic Study of Vincristine in Children With Leukemia NCT00001689 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Multicenter Study of 9-Aminocamptothecin (9-AC) in Patients With Refractory Leukemia NCT00251368 | Dana-Farber Cancer Institute | Phase 1 |